| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/20/2000 | WO2000024885A3 p53 MORPHOLINO-BASED ANTISENSE |
| 07/20/2000 | WO2000021979A3 Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
| 07/20/2000 | WO2000020590A3 G-protein coupled receptor proteins |
| 07/20/2000 | WO2000020041A3 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 07/20/2000 | WO2000018418A3 Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester |
| 07/20/2000 | WO2000015246A3 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 07/20/2000 | WO2000010598B1 Recombinant botulinium toxin for the treatment of mucus hypersecretion |
| 07/20/2000 | WO2000004917A3 USE OF HC gp-39 IN IMMUNE DISEASES |
| 07/20/2000 | WO2000003709A9 Novel dna-cleaving antitumor agents |
| 07/20/2000 | WO2000002902A9 Novel inhibitors of angiogenesis and tumor growth |
| 07/20/2000 | WO2000001687A9 Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 07/20/2000 | WO1999064048A9 Inhibitors of hiv reverse transcriptase |
| 07/20/2000 | WO1997025042A8 Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x |
| 07/20/2000 | DE19901008A1 Peptide zur Inhibierung von HPV E6-Proteinen Peptides for inhibition of HPV-E6 proteins |
| 07/20/2000 | DE19855704A1 Mittel zur Behandlung der Symptome der Parkinsonschen Krankheit Agents for treating the symptoms of Parkinson's disease |
| 07/20/2000 | CA2724287A1 Bifidobacterium in the treatment of inflammatory disease |
| 07/20/2000 | CA2697598A1 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | CA2370042A1 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | CA2360584A1 Mammalian alpha-helical protein - 12 |
| 07/20/2000 | CA2360581A1 A novel method for designing protein kinase inhibitors |
| 07/20/2000 | CA2360488A1 Use of a plant extract of the genus rosmarinus in compositions for treating ageing skin symptoms |
| 07/20/2000 | CA2360464A1 Human peptidases |
| 07/20/2000 | CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2360358A1 Compositions having improved stability |
| 07/20/2000 | CA2360356A1 .beta.-phenylalanine derivatives as integrin antagonists |
| 07/20/2000 | CA2360268A1 Pre-conditioning against cell death |
| 07/20/2000 | CA2360243A1 Use of lactobacillus salivarius |
| 07/20/2000 | CA2360232A1 Telomerase inhibitors |
| 07/20/2000 | CA2359990A1 Novel aralkyl amines of spirofuropyridines useful in therapy |
| 07/20/2000 | CA2359980A1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 07/20/2000 | CA2359952A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | CA2359942A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | CA2359795A1 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| 07/20/2000 | CA2359569A1 Reductive alkylation of secondary amines with hydrosilane |
| 07/20/2000 | CA2359479A1 Novel complex-forming proteins |
| 07/20/2000 | CA2359474A1 Particles for oral delivery of peptides and proteins |
| 07/20/2000 | CA2359449A1 Phenanthridine-n-oxides with pde-iv inhibiting activity |
| 07/20/2000 | CA2359416A1 6-arylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2359392A1 Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
| 07/20/2000 | CA2359345A1 Methods for making proteins containing free cysteine residues |
| 07/20/2000 | CA2359067A1 Polypeptide variants with altered effector function |
| 07/20/2000 | CA2358693A1 Anti-ccr4 antibodies and methods of use therefor |
| 07/20/2000 | CA2358684A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 07/20/2000 | CA2356532A1 Noninvasive vascular therapy |
| 07/20/2000 | CA2355792A1 New amidinobenzylamine derivatives and their use as thrombin inhibitors |
| 07/20/2000 | CA2353088A1 Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors |
| 07/20/2000 | CA2349832A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | CA2349180A1 Anthranilic acid derivatives |
| 07/20/2000 | CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/20/2000 | CA2296224A1 Use of imidazo(1,5-a)pyrido(3,2-e)pyrazinones |
| 07/19/2000 | EP1020464A1 Paroxetine methansulfonate |
| 07/19/2000 | EP1020463A1 Paroxetine methanesulfonate |
| 07/19/2000 | EP1020439A1 Cetp activity inhibitors |
| 07/19/2000 | EP1020190A2 Treatment of BPH with cGMP elevators |
| 07/19/2000 | EP1020187A1 Pharmaceutical compositions containing hydroximic acid derivatives |
| 07/19/2000 | EP1019726A1 Prevention of sudden infant death |
| 07/19/2000 | EP1019533A1 Silanol enzyme inhibitors |
| 07/19/2000 | EP1019530A1 A method of treating cancer |
| 07/19/2000 | EP1019529A1 A method of treating cancer |
| 07/19/2000 | EP1019513A1 Ikr-1 and ikr-2, protein kinases which are related to the i kappa b kinases |
| 07/19/2000 | EP1019506A1 101 human secreted proteins |
| 07/19/2000 | EP1019500A2 Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons |
| 07/19/2000 | EP1019497A1 Hammerhead ribozymes with extended cleavage rule |
| 07/19/2000 | EP1019490A2 Methods for modulating hematopoiesis and vascular growth |
| 07/19/2000 | EP1019442A1 Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics |
| 07/19/2000 | EP1019439A1 Soluble single-chain t-cell receptor proteins |
| 07/19/2000 | EP1019435A1 Amplification of response from expressed recombinant protein |
| 07/19/2000 | EP1019434A2 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis |
| 07/19/2000 | EP1019431A1 Novel rnase p |
| 07/19/2000 | EP1019412A1 Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht 1d? receptor antagonists |
| 07/19/2000 | EP1019410A1 Spiro-piperidine derivatives and their use as tachykinin antagonists |
| 07/19/2000 | EP1019409A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 07/19/2000 | EP1019406A1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 07/19/2000 | EP1019400A1 Benzo(5,6)cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors |
| 07/19/2000 | EP1019399A1 Aryl thiophene derivatives as pde iv inhibitors |
| 07/19/2000 | EP1019396A1 Novel cycloalkyl substituted imidazoles |
| 07/19/2000 | EP1019395A1 Farnesyl transferase inhibiting 2-quinolone derivatives |
| 07/19/2000 | EP1019394A1 PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| 07/19/2000 | EP1019392A1 Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 07/19/2000 | EP1019391A1 Inhibitors of prenyl-protein transferase |
| 07/19/2000 | EP1019389A2 Epothilone derivatives |
| 07/19/2000 | EP1019387A1 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
| 07/19/2000 | EP1019386A1 Reverse hydroxamate derivatives as metalloprotease inhibitors |
| 07/19/2000 | EP1019385A1 Aminoaryl oxazolidinone n-oxides |
| 07/19/2000 | EP1019382A1 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| 07/19/2000 | EP1019380A2 Tricyclic 3-oxo-propanenitrile compounds |
| 07/19/2000 | EP1019373A1 Novel human nk 3? receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them |
| 07/19/2000 | EP1019372A1 Novel fused pyrrolecarboxamides; a new class of gaba brain receptor ligands |
| 07/19/2000 | EP1019370A1 Ace-inhibitor nitric salts |
| 07/19/2000 | EP1019364A2 Inhibitors of protein tyrosine phosphatase |
| 07/19/2000 | EP1019360A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 07/19/2000 | EP1019358A1 Novel compounds, their use and preparation |
| 07/19/2000 | EP1019089A2 Long-acting drugs and pharmaceutical compositions comprising them |
| 07/19/2000 | EP1019083A1 Methods and compositions for the selective modification of nucleic acids |
| 07/19/2000 | EP1019082A1 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 07/19/2000 | EP1019081A2 Apolipoprotein e/growth factor complexes and methods of use |
| 07/19/2000 | EP1019079A1 Modulation of nitric oxide production |
| 07/19/2000 | EP1019075A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 07/19/2000 | EP1019071A2 Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods |
| 07/19/2000 | EP1019070A1 Bradykinin analogs as selective inhibitors of cell activation |